Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
104138-64-9
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human alpha-galactosidase Aenzyme replacement therapy (ERT) biologic
Mechanism of action
Provides exogenous alpha-galactosidase A activity to hydrolyse globotriaosylceramide (GL-3) and related glycosphingolipid substrates that accumulate because of deficient endogenous enzyme activity in Fabry disease. Agalsidase alfa and agalsidase beta are distinct recombinant products; the exact product should be identified before product-specific use is assigned.
Indications / reported uses
Long-term enzyme replacement therapy for patients with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency); dosing, age eligibility and product information are specific to agalsidase alfa or beta
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Agalsidase PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Agalsidase Permitted Daily Exposure (PDE) report (the Agalsidase PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Agalsidase Occupational Exposure Limit (OEL) report (the Agalsidase OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.